SEC-sourced researchBeta

TLSIW

TriSalus Life Sciences, Inc.

US markets

Data passport

CIK: 0001826667
Exchange: Nasdaq
Business activity: — · SIC 3841
Financial inputs: 6/6
Filing date: Oct 7, 2026
SEC registry record: Operating company

Last updated: Oct 8, 2026, 11:04 AM UTCSEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Chart metric

TLSIW · Exact amounts and source periods · USD
Period end	Revenue	Filing date
December 2024	29,431,000.0000	Mar 5, 2026
December 2025	45,151,000.0000	Mar 5, 2026

Annual periods · USD

Period end	Revenue	Net income	Operating cash flow	Total assets	Total liabilities	Filing date
December 2025	45,151,000.0000	-39,227,000.0000	-18,012,000.0000	35,331,000.0000	69,192,000.0000	Mar 5, 2026
December 2024	29,431,000.0000	-30,045,000.0000	-40,843,000.0000	23,971,000.0000	49,865,000.0000	Mar 5, 2026

Financial inputs behind the calculation

Financial inputs	USD	Period end	Filing date	Form
RevenueRevenueFromContractWithCustomerExcludingAssessedTax	$45.15M	December 2025	Mar 5, 2026	10-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax	$29.43M	December 2024	Mar 5, 2026	10-K
Net incomeNetIncomeLoss	-$39.23M	December 2025	Mar 5, 2026	10-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities	-$18.01M	December 2025	Mar 5, 2026	10-K
Total assetsAssets	$35.33M	December 2025	Mar 5, 2026	10-K
Total liabilitiesLiabilities	$69.19M	December 2025	Mar 5, 2026	10-K

New filings

Explore methodology ↗